BACKGROUND
==========

Wine polyphenols have been postulated to have many favourable effects \[[@B1], [@B2], [@B3], [@B4]\] but most of this data has been obtained in vitro \[[@B5], [@B6]\]. Grape seed extracts (GSEs) contain a high concentration of many of the polyphenols in grape skins, in particular, the proanthocyanidins, which are also found in red wine. Green tea also contains polyphenols, in particular, the catechins, which are believed to mediate many of the cancer chemopreventive effects \[[@B7]\]. Green tea has been epidemiologically associated with protection from both cancer and heart disease \[[@B8]\]. Although there is abundant in vitro evidence that polyphenols have antioxidant and anticancer effects, there is a dearth of animal and human experiments \[[@B9]\]. CSIRO data (unpublished) indicates that GSEs inhibit low-density lipoprotein (LDL) oxidation and reduce aortic ring constriction in vitro. Extract of oligomeric proanthocyanidins from other sources such as Pycnogenol from pine bark enhances nitric oxide (NO) production from vascular endothelium in vitro \[[@B10]\]. Grape seed proanthocyanidin extract (GSPE, 0.1% level) has been shown to reduce atherosclerosis in cholesterol-fed rabbits by 30%--50% probably by inhibiting LDL oxidation as lipid levels were not altered while malondialdehyde levels in the aorta (an index of lipid oxidation) were reduced by 25% \[[@B11]\]. Plasma proanthocyanidins were not detectable, suggesting that absorption is very low. Rats given a dose as a single bolus do have low (0.5 *μ*M) but detectable levels. The dose of GSPE was equivalent to a dose of 3.5 g for a 70 kg human \[[@B12]\]. Most over-the-counter forms of GPSE are in doses of 50--100 mg with a recommendation to take 1 capsule/day. This material has been available for many years and is regarded as safe and nontoxic.

Quercetin, a flavanoid prominent in onions and apples, has been epidemiologically associated with protection from coronary artery disease and cancer \[[@B13], [@B14]\] and is now available over the counter in 300--500 mg dose forms, with daily doses of up to 1500 mg. No clinical trials in the cardiovascular area have been performed with quercetin although it has been shown to inhibit monocyte adhesion to endothelial cells \[[@B15]\]. This is believed to be the first step in the process of atherosclerosis. One trial using 4 g/day has shown no effects on lipids, blood pressure, or platelet activation in normal volunteers \[[@B16]\].

###### 

Cardiovascular measures produced by the HDI compliance instrument; mean of 35 complete measures ± SD.

  --------------------------------------------- ------------ ------------ --------------- ------------
                                                Baseline     GSE          GSE/quercetin   Control
                                                                                          
  Systolic BP (mmHg)                            127 ± 15     124 ± 14     125 ± 11        124 ± 13
  Diastolic BP (mmHg)                           74 ± 9       73 ± 8       73 ± 10         73 ± 9
  Mean BP (mmHg)                                94 ± 13      91 ± 18      94 ± 12         91 ± 12
  Pulse pressure (mmHg)                         53 ± 9       51 ± 8       51 ± 7          51 ± 8
  Pulse rate (beats/min)                        58 ± 8       59 ± 8       58 ± 7          57 ± 7
  Estimated cardiac ejection time (ms)          335 ± 25     337 ± 24     336 ± 23        333 ± 36
  Estimated stroke volume (mL)                  93 ± 13      92 ± 12      93 ± 12         94 ± 12
  Estimated stroke volume index (mL/m^2^)       47 ± 5       47 ± 4       47 ± 4          47 ± 6
  Estimated cardiac output (L/min)              5.4 ± 0.7    5.5 ± 0.7    5.5 ± 0.7       5.4 ± 0.7
  Estimated cardiac output index (L/min/m^2^)   2.8 ± 0.2    2.7 ± 0.3    2.8 ± 0.3       2.7 ± 0.2
  Large artery elasticity index                 17.5 ± 4.6   18.4 ± 4.8   18.7 ± 6.1      18.2 ± 4.7
  Small artery elasticity index                 7.4 ± 3.8    7.4 ± 3.4    7.9 ± 3.9       7.4 ± 3.2
  Systemic vascular resistance                  1364 ± 275   1345 ± 229   1364 ± 221      1352 ± 209
  Total vascular impedance                      131 ± 32     124 ± 33     125 ± 35        127 ± 35
  --------------------------------------------- ------------ ------------ --------------- ------------

###### 

Flow-mediated dilatation as measured by ultrasound. *N* = 35, mean SD. Treatments with different superscripts are different at $P < .05$.

  ----------------------- ---------------- ---------------- --------------- ----------------
                          Baseline         GSE              GSE/quercetin   Control
                                                                            
  Precompression cm^−2^   44.3 ± 6.3       45.1 ± 6.4       45.9 ± 7.2      45.5 ± 7.3
                                                                            
  Postcompression         46.2 ± 5.8       47.4 ± 6.5       47.6 ± 7.5      47.3 ± 7.3
                          (*n* = 30)       (*n* = 35)       (*n* = 32)      (*n* = 36)
                                                                            
  Change                  1.9^1,2^ ± 1.3   2.3^1^ ± 1.4     1.7^2^ ± 1.0    1.8^2^ ± 1.3
                          (4.3%)           (5.1%)           (3.7%)          (4.0%)
                                                                            
  Pre-GTN                 44.8 ± 7.1       45.8 ± 7.1       46.9 ± 7.5      46.2 ± 7.1
                                                                            
  Post-GTN                52.1 ± 6.8       52.7 ± 6.9       52.9 ± 7.3      52.8 ± 7.0
                          (*n* = 38)       (*n* = 30)       (*n* = 29)      (*n* = 31)
                                                                            
  Change                  7.3^1^ ± 2.4     6.9^1,2^ ± 2.3   6.0^2^ ± 3.0    6.5^1,2^ ± 1.8
                          (16.3%)          (15.1%)          (12.8%)         (14.1%)
  ----------------------- ---------------- ---------------- --------------- ----------------

###### 

Effect of GSE and GSE/quercetin on serum lipids mean (mmol/L) ± SD.

  ------------------- ------------------- ------------- ------------- ------------- ------------- --------------- -------------
                      Period 1 baseline   Period 2      Period 3      Period 4      GSE           GSE/quercetin   Control
                                                                                                                  
  Total cholesterol   6.57 ± 1.07         6.63 ± 1.06   6.59 ± 0.99   6.58 ± 1.06   6.63 ± 0.93   6.64 ± 1.10     6.64 ± 1.05
  Triglyceride        1.80 ± 0.80         1.98 ± 1.06   1.90 ± 0.83   1.73 ± 0.88   1.88 ± 0.92   1.88 ± 0.85     1.92 ± 1.03
  HDL cholesterol     1.18 ± 0.31         1.18 ± 0.31   1.19 ± 0.34   1.16 ± 0.33   1.18 ± 0.33   1.16 ± 0.34     1.15 ± 0.31
  LDL cholesterol     4.59 ± 0.98         4.56 ± 0.93   4.55 ± 0.93   4.65 ± 0.98   4.61 ± 0.83   4.62 ± 1.00     4.63 ± 0.99
  ------------------- ------------------- ------------- ------------- ------------- ------------- --------------- -------------

###### 

Effect of GSE and GSE/quercetin on plasma CRP, nitrate/nitrite, and adhesion molecules. *N* = 35, mean SD.

  -------------------- ------------------- ------------- ------------- ------------- ------------- --------------- -------------
                       Period 1 baseline   Period 2      Period 3      Period 4      GSE           GSE/quercetin   Control
                                                                                                                   
  CRP (mg/L)           ---                 3.63 ± 5.01   3.48 ± 4.19   3.69 ± 4.17   3.40 ± 3.53   3.63 ± 5.10     3.73 ± 4.64
  Nitrate (*μ*mol/L)   31.1 ± 12.7         28.0 ± 11.0   36.9 ± 36.7   30.0 ± 13.2   35.6 ± 36.7   30.5 ± 12.4     28.4 ± 12.7
  ICAM1 (*μ*g/mL)      ---                 0.49 ± 0.10   0.49 ± 0.11   0.48 ± 0.11   0.49 ± 0.11   0.48 ± 0.11     0.49 ± 0.11
  VCAM1 (*μ*g/mL)      ---                 0.99 ± 0.28   0.99 ± 0.22   1.00 ± 0.24   0.98 ± 0.20   0.98 ± 0.26     1.02 ± 0.27
  -------------------- ------------------- ------------- ------------- ------------- ------------- --------------- -------------

###### 

Effect of GSE and GSE/quercetin on clotting and fibrinolytic factors. *N* = 35, mean SD.

  -------------------- --------------- ---------------- ---------------- ---------------- ---------------- ---------------- ----------------
                       Baseline        Period 2         Period 3         Period 4         GSE              GSE/quercetin    Control
                                                                                                                            
  VWF (%)              ---             115.58 ± 39.12   101.66 ± 35.82   102.37 ± 35.55   109.11 ± 36.06   104.50 ± 39.58   106.00 ± 36.40
  PAI-1 ng/mL          ---             50.47 ± 33.51    45.22 ± 21.41    49.27 ± 31.72    50.47 ± 35.77    48.58 ± 29.24    45.90 ± 21.41
  PAI-1 activity       16.45 ± 9.72    16.27 ± 9.08     16.28 ± 8.05     16.28 ± 10.37    15.39 ± 9.30     16.78 ± 10.05    16.76 ± 8.13
  tPA (ng/mL)          ---             7.235 ± 3.396    6.636 ± 2.350    6.857 ± 2.378    6.929 ± 2.686    6.908 ± 2.835    6.891 ± 2.766
  tPA activity         1.432 ± 1.204   1.295 ± 0.865    1.140 ± 0.715    1.269 ± 1.011    1.261 ± 0.822    1.146 ± 0.764    1.297 ± 1.011
  tPA/PAI-1 activity   20.37 ± 21.63   20.91 ± 21.15    24.46 ± 24.06    27.11 ± 32.45    24.12 ± 27.75    26.05 ± 29.90    23.04 ± 21.3
  tPA/PAI-1 mass       ---             0.205 ± 0.348    0.188 ± 0.483    0.194 ± 0.648    0.187 ± 0.119    0.206 ± 0.179    0.195 ± 0.138
  -------------------- --------------- ---------------- ---------------- ---------------- ---------------- ---------------- ----------------

###### 

Effect of GSE and GSE/quercetin on urine isoprostane (iso PGF2*α*). *N* = 35, mean SD.

  ------------------------------ -------------- -------------- -------------- -------------- --------------- --------------
                                 Period 2       Period 3       Period 4       GSE            GSE/quercetin   Control
                                                                                                             
  Isoprostane (pg/mL)            617 ± 348      713 ± 507      709 ± 578      668 ± 407      741 ± 644       630 ± 362
  Creatinine (mmol/L)            11.59 ± 4.92   11.37 ± 5.51   12.72 ± 5.46   11.59 ± 4.92   11.69 ± 5.23    12.72 ± 5.46
  Isoprostane/creatinine pg/mg   529 ± 392      561 ± 327      519 ± 328      534 ± 362      562 ± 416       513 ± 254
  Isoprostane excretion ng/d     1178 ± 986     1243 ± 1220    1107 ± 743     1147 ± 407     1270 ± 1348     1112 ± 694
  ------------------------------ -------------- -------------- -------------- -------------- --------------- --------------

###### 

Effect of GSE and GSE/quercetin on oxidised LDL levels U/L; *N* = 35, mean SD.

  --------------- --------------- --------------- --------------- --------------- ---------------
  Period 2        Period 3        Period 4        GSE             GSE/quercetin   Control
                                                                                  
  94973 ± 26906   94637 ± 24862   94359 ± 31705   95284 ± 24563   99142 ± 22728   98383 ± 22973
  --------------- --------------- --------------- --------------- --------------- ---------------

In this study we hypothesised that 2 g/day of GSE would improve flow-mediated dilatation (FMD) and this might be mediated by changes in the production of NO. We also hypothesised that GSE and quercetin would function as antioxidants in plasma, reduce the level of F2 isoprostane in urine, and possibly influence the level of oxidized LDL in plasma and, secondary to this, reduce the activation of the endothelium. This would be assessed by changes in adhesion, clotting, and fibrinolytic molecules.

METHODS
=======

Subjects
--------

Forty-three men and women with above-average vascular risk due to high cholesterol, smoking, or high blood pressure were recruited by public advertisement and screened at the Clinical Research Unit, CSIRO Health Sciences and Nutrition, Adelaide. There were no exclusion criteria on the basis of medication or consumption of alcohol. Subjects were excluded if their body mass index (BMI) was greater than 35 or if they suffered from diabetes mellitus, untreated metabolic disorders such as thyroid or adrenal disease, liver or kidney disease, or unstable coronary artery disease. All subjects gave written, informed consent and the protocol was approved by the Human Ethics Committee of CSIRO.

The trial was 12 weeks long and consisted of 3 four-week periods of a double-blind randomised crossover with control and active ingredients (1 g GSE from Tarac +/− 0.5 g quercetin) in 240 g of yoghurt taken twice daily. Blood samples and vascular compliance measures were taken at baseline and at the end of each period. The background diet was a low-polyphenol, low-quercetin diet. This was achieved by restricting tea and coffee to a maximum of 2 cups per day, restricting apples to one per day, and forbidding red wine and onions throughout the 12 weeks. Measures included FMD using ultrasound, vascular compliance using radial pulse analysis (Hypertension Diagnostics Inc/PulseWave CR-2000), fasting lipids, oxidized LDL, nitrates (to assess the antioxidant effects), C reactive protein (CRP), von Willebrand factor (VWF), tissue-type plasminogen activator (tPA), plasminogen activator inhibitor 1 (PAI-1), vascular cell adhesion molecule (VCAM1), and intercellular adhesion molecule 1 (ICAM-1). Twenty-four-hour urine was collected to measure the oxidized lipid isoprostane F~2*α*~.

FMD was assessed in the brachial artery after blockage of blood flow in the forearm with a blood pressure cuff at 200 mmHg for 5 minutes. The response of the vessel 5 minutes after administration of 100 *μ*g of glyceryl trinitrate (GTN) sublingually was also assessed \[[@B17]\].

Serum lipids
------------

Serum lipids (total cholesterol, triglyceride, HDL cholesterol) were measured on 2 consecutive days at baseline and at the end of each 3-week intervention period. Venous blood samples (20 mL) were taken into plain tubes after an overnight fast of 12 hour. Serum was separated by low-speed centrifugation at 600 g for 10 minutes at 5^°^C (GS-6R centrifuge; Beckman, Fullerton, Calif) and frozen at −20^°^C. At the end of the study, all samples from each subject were analysed within the same analytic run. Total cholesterol and triacylglycerol were measured on a Cobas-Bio centrifugal analyzer (Roche Diagnostica, Basel, Switzerland) using enzymatic kits (Hofmann-La Roche Diagnostica, Basel, Switzerland) and standard control sera. Plasma HDL-cholesterol concentrations were measured after precipitation of apoB containing lipoproteins by PEG 6000. The coefficients of variation for the individual lipids were all less than 5%. The following modification of the Friedewald equation for molar concentrations was used to calculate LDL cholesterol in mmol/L: total cholesterol---(triacylglycerol/2.18)---HDL cholesterol.

All other tests were enzyme linked immunosorbent assays (ELISAs): VWF (Helena Laboratories, Melbourne Australia), Coaliza tPA (Chromogenix, Sweden), Coaset tPA (Chromogenix), Coaliza PAI-1 (Chromogenix), Coatest PAI-1 (Chromogenix), oxidised LDL: Mercodia oxidised LDL ELISA (Mercodia, Sweden), SVCAM1 (Immunokontact, Sweden), ICAM1 (Immunokontact), CRP (Alpha Diagnostic International, Texas), 8-isoprostane (8-iso PGF2*α*) (Cayman Chemical), nitrate/nitrite assay kit (Cayman Chemical).

Statistical analysis
--------------------

Repeated measures analysis of variance was calculated with type of yoghurt as the within-subject factor and with sex and order as the between-subject factors. Where there was a significant treatment effect detected by repeated measures, paired Student $t$ tests were used to locate differences. Bivariate correlation was conducted using Pearson\'s correlation coefficient. Analyses were performed with SPSS 10.0 for Windows (SPSS Inc, Chicago, Ill). Significance was set at $P < .05$.

RESULTS AND DISCUSSION
======================

Twelve women and twenty-four men completed the study and one additional woman missed the last phase of treatment. Six subjects withdrew after commencement and 6 withdrew prior to commencement.

The risk profile of subjects was as follows: 6 subjects had high blood pressure (5 on medication), 3 were smokers, and 31 had high cholesterol (greater than 5 mmol/L on finger prick). Two volunteers on atorvastatin to lower cholesterol stopped the medication prior to beginning the trial. The average cholesterol was 6.5 mmol/L (range 4.68 to 8.63), average age 58 years (range 34--70), weight 83.1 Kg (63.1 kg to 118.7 kg), BMI 28.4 (19.8--37.5). Mean blood pressure was 127 mm Hg systolic and 74 mm Hg diastolic.

Blood pressure/vascular compliance
----------------------------------

There was a weak ($P < .05$) trend to a lowering of systolic blood pressure over the duration of the trial with a fall from 127 mm Hg at baseline to 124 mm Hg at week 12. This is quite usual in clinical trials in which blood pressure is measured. There were no changes in any vascular parameter with treatment (see [Table 1](#T1){ref-type="table"}).

Flow-mediated dilatation after compression release and GTN dilatation
---------------------------------------------------------------------

GSE alone produced an absolute 1.1% greater dilatation compared with control ($P < .05$) but the addition of quercetin apparently nullified this completely. GTN-induced dilatation was not influenced by GSE but quercetin again appeared to diminish the response compared with baseline ($P < .05$), but not compared with control.

This indicates that GSE favourably influences the endothelium enhancing NO production, release or slowing down oxidative destruction of it, but quercetin appears to interfere with this. It is known that quercetin inhibits LPS-induced NO release in RAW 264.7 macrophages \[[@B18]\] and can act as a prooxidant in other systems \[[@B19], [@B20], [@B21]\] at both low and high levels (see [Table 2](#T2){ref-type="table"}).

Serum lipids
------------

No changes were noted but none were expected. Subjects were at high risk of cardiovascular disease by virtue of the high average cholesterol (see [Table 3](#T3){ref-type="table"}).

C reactive protein
------------------

CRP is an acute-phase protein produced by the liver in response to tissue damage or inflammation and may increase 500 fold acutely \[[@B22]\]. It is also elevated but to low levels by low-grade inflammatory conditions such as atherosclerosis and can be used to predict clinical events \[[@B23]\]. Statins which lower cholesterol by inhibiting synthesis in the liver also lower CRP and the mechanism appears to be unrelated to the degree of cholesterol lowering \[[@B24]\]. It may be related to their antioxidant activity or a direct anti-inflammatory activity. Thus in this study it was used to check both for potential toxic effects and to demonstrate a potential of GSE to act like a statin in the vessel wall. No differences were found between periods or treatments. One person was excluded as he had a respiratory infection requiring antibiotics which caused a sharp rise in CRP levels (over a 100-fold rise) (see [Table 4](#T4){ref-type="table"}).

Nitrate/Nitrite
---------------

Plasma nitrate was measured as a surrogate index of NO production \[[@B25], [@B26]\]. NO is an endogenous vasodilator produced by endothelial cells. Red wine polyphenols enhance vasorelaxation and NO production in vitro \[[@B27], [@B28]\]. Ethanol itself also enhances NO production \[[@B29]\]. No differences were found either by period or by treatment with or without an outlier whose value rose 6-fold in the GSE period. However, dietary nitrites and nitrates can confound this measure quite easily so the absence of change does not mean that NO production did not rise (see [Table 4](#T4){ref-type="table"}).

Adhesion molecules
------------------

ICAM1 and VCAM1 are molecules which bind white cells to the endothelium and reflect the state of the health of the endothelium, particularly in relationship to atherosclerosis \[[@B30], [@B31]\]. If the endothelium is damaged by oxidized lipid, cigarette smoke, or high blood pressure, these markers increase \[[@B32]\]. An antioxidant might be expected to lower the level of these markers (vitamin E does in some studies \[[@B33]\]) as does a statin which lowers plasma lipid level \[[@B34]\]. Polyphenols from blue and red berries reduce adhesion molecules in endothelial cells in vitro \[[@B35]\]. GSE and GSE/quercetin had no effect, nor were there any time effects (see [Table 4](#T4){ref-type="table"}).

Clotting and fibrinolytic factors
---------------------------------

VWF mediates the binding of platelets to injured vessels and protects coagulation factor VIII. It is produced in the endothelium and is released when the endothelium is damaged by atherosclerosis, diabetes, insulin resistance, or hypertension \[[@B36], [@B37], [@B38]\]. Tissue-type plasminogen activator is released from endothelial cells to initiate the process of breaking down clots in the vessel by activating plasminogen to plasmin which then breaks down fibrin. Endothelial dysfunction impairs the release of active tPA \[[@B39]\] and is associated with an enhanced release of PAI-1 \[[@B40]\]. GSE and GSE/quercetin had no effect on VWF, tPA, or PAI-1 and there were no time effects. In \[[@B41]\] de Maat et al found no effect of black or green tea on any of the markers we measured, but wine polyphenolics have been shown in cultured human endothelial cells \[[@B42]\] to increase production of tPA (see [Table 5](#T5){ref-type="table"}).

Urine isoprostanes
------------------

8-Isoprostane (8-iso PGF2*α*) is a stable end product formed from arachidonic acid by free radical action and is measurable in plasma and urine. The level is believed to represent the degree of oxidative stress in lipids \[[@B43], [@B44]\].

In this experiment, we saw no changes in urinary isoprostanes either absolute or expressed in relation to creatinine to adjust for incomplete urinary collections (see [Table 6](#T6){ref-type="table"}). The values measured in this study were in the range described for subjects with type 2 diabetes. Vitamin E has been shown to reduce plasma and urine isoprostanes in some studies \[[@B45], [@B46]\] but not in others \[[@B47]\]. Subjects with type 2 diabetes have elevated (double) level of urinary isoprostane compared with controls and it falls by 32% with treatment with vitamin E \[[@B48]\]. Ide et al \[[@B49]\] found that in healthy young men vitamin E could reduce urine isoprostane levels by 48%. Whole grains have been found to lower isoprostane by 28% in one study \[[@B50]\], as did fruit and vegetables in another study \[[@B51]\], although van den Berg found no effects of fruit and vegetables \[[@B52]\]. Tea polyphenols did not alter isoprostanes \[[@B53]\] while dealcoholised red wine reduced the levels in plasma with a trend in urine \[[@B54]\].

Although the results are negative except for the FMD changes, they are not incompatible with the current literature which is not uniform in its results. They are also compatible with the observed lack of change in the levels of oxidized LDL (see [Table 7](#T7){ref-type="table"}) in this study. There is no published data on measurement of oxidized LDL in plasma using this method.

There were no changes in urine chemistry, haematology, clotting, or biochemistry with GSE or GSE/quercetin. There were some time-related changes in urea and creatinine chloride and bicarbonate which may have been due to warmer weather (data not shown).

CONCLUSIONS
===========

We have demonstrated that sufficient antioxidant polyphenols from GSE were absorbed to influence FMD but no other endothelial functions were affected. It is known from rat and rabbit studies that the absorption of proanthycyanidins from GSE is very limited. In one rat study \[[@B55]\], after feeding 0.25 g/kg of GSE (equivalent to feeding over 20 g to humans), a level of 18 *μ*g/mL of dimer was achieved after 1 hour. In the rabbits, despite an equivalent dose spread over the day, no proanthocyanidins were detected, even though in this model lipid peroxidation and aortic atherosclerosis were reduced \[[@B11]\]. In vitro studies often use levels of 10--50 *μ*g/mL \[[@B6]\] which is 10--20 times higher than what might be achieved in human studies. Quercetin is known to be absorbed and 1 g/day can produce levels 23 times higher than control capsules. Despite this level and its demonstrable in vitro antioxidant action, it has no effects on platelets or lipids \[[@B56]\]. Although red wine extract inhibits endothelin (ET-1) production, neither isolated red wine polyphenols (quercetin, resveratrol, D-,L-catechin, D-,L-epicatechin) nor the anthocyanins delphinidin, pelargonidin, cyanidin, peonidin, petunidin, or malvidin affect ET-1 production \[[@B6]\].

Although there is no data yet relating impaired FMD to cardiac events in subjects without coronary disease, those patients with coronary disease who have very impaired FMD have more events \[[@B57]\]. Subjects with impaired FMD are more likely to have coronary disease on angiography \[[@B58]\]. Statins improve mortality and one mechanism may be via their improvement of FMD \[[@B59]\]. Subjects with low acetylcholine induced forearm vasodilatation are more likely to have acute events \[[@B60]\].
